ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Li-Fraumeni Syndrome
Gene/Gene Panel: TP53
Context: Adult
Date
Status
Release
Outcomes-Interventions
Notes
2024/03/24
Released
3.0.3
A
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 9CD
System migration to fix the sem versioning
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 ⇔ 0018875 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2024/03/24
Released (Under revision)
A
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 9CD
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 ⇔ 0018875 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2023/07/14
Released
A
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 9CD
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 ⇔ 0018875 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2023/07/14
Released (Under revision)
3.0.1
A
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 9CD
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 ⇔ 0007903 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2022/02/09
Released
3.0.1
A
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 9CD
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 ⇔ 0007903 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2022/02/09
Released (Under revision)
3.0.0
A
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 9CD
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 ⇔ 0007903 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2021/07/19
Released
3.0.0
A
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 9CD
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 ⇔ 0007903 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2021/06/16
Released (Under revision)
2.2.1
A
Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 9CB
MONDO IDs added, scoring groups unadjusted.
2020/12/23
Released
2.2.1
A
Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 9CB
MONDO IDs added, scoring groups unadjusted.
2020/02/18
Released (Under revision)
2.2.0
A
Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 9CB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/10/03
Released
2.2.0
A
Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 9CB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/04/04
Released
2.1.0
A
Li Fraumeni syndrome-associated cancers
Avoidance of radiotherapy 9CB
Cancer surveillance 9CB
Internal system migration related to merging adult and pediatric contexts.
2018/11/01
Released
2.0.1
A
Li Fraumeni syndrome-associated cancers
Avoidance of radiotherapy 9CB
Cancer surveillance 9CB
Internal system migration related to score text replacement from E to N
2018/02/28
Released
2.0.0
A
Li Fraumeni syndrome-associated cancers
Avoidance of radiotherapy 9CB
Cancer surveillance 9CB
2018/02/12
Released (Under revision)
1.0.0
A
Adrenocortical tumors
Avoidance of radio therapy 10CC
Surveillance 10CE
Breast cancer
Avoidance of radio therapy 10CC
Cancer specific or general surveillance 10CB
Risk reducing surgery 9CC
CNS Tumors
Avoidance of radio therapy 10CC
Surveillance 9CC
Colorectal cancer
Avoidance of radio therapy 10CC
Cancer specific or general surveillance 10CC
Risk reducing surgery 9CC
Ovarian cancer
Avoidance of radio therapy 10CC
Cancer specific or general surveillance 8CC
Risk reducing surgery 9CC
Sarcomas
Avoidance of radio therapy 10CC
Surveillance 10CE
2018/01/11
Released
1.0.0
A
Adrenocortical tumors
Avoidance of radio therapy 10CC
Surveillance 10CE
Breast cancer
Avoidance of radio therapy 10CC
Cancer specific or general surveillance 10CB
Risk reducing surgery 9CC
CNS Tumors
Avoidance of radio therapy 10CC
Surveillance 9CC
Colorectal cancer
Avoidance of radio therapy 10CC
Cancer specific or general surveillance 10CC
Risk reducing surgery 9CC
Ovarian cancer
Avoidance of radio therapy 10CC
Cancer specific or general surveillance 8CC
Risk reducing surgery 9CC
Sarcomas
Avoidance of radio therapy 10CC
Surveillance 10CE
¤ Powered by BCM's Genboree.